explore -WSS

explore

author：hotspot 2025-10-01 02:13:18 - browse：21

Matts Take Column Illustration — Molly Ferguson for STAT

What do you say to a patient when the FDA rejects “their” experimental drug — one that they believe can alleviate at least some of their suffering?

That question arises in the aftermath of a dramatic moment at the Food and Drug Administration last week. Over the FDA’s protests, a small biotechnology company called BrainStorm Cell Therapeutics had insisted that the agency evaluate its experimental treatment for amyotrophic lateral sclerosis, or ALS, brand named NurOwn. ALS patients made fervent pleas for the medicine, a type of stem cell preparation, based on reports on social media and re-analyses of the data that they thought indicated it might be of some help to those with the fatal disease.

But the FDA methodically dismantled BrainStorm’s application. The medicine couldn’t work the way the company said it would, the agency insisted; the clinical trials didn’t show it was effective; and it was not clear BrainStorm could manufacture the medicine with sufficient quality. Worst of all, more patients died among those who received the drug than those who got placebo. The FDA’s panel of expert advisers voted 17 to 1 that the medicine was not safe and effective, with one person abstaining. The agency doesn’t have to follow the panel’s advice but probably will.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： FDA approves potent Eli Lilly obesity drug, Zepbound

WSS

FDA approves Recor Medical high blood pressure device

Just how powerful is the placebo effect?

STAT Executive Editor Rick Berke on STAT's 8th birthday

ACIP vaccine advisory panel sees its vacancies filled

Removing probiotics from the NICU could threaten preemies' health

Excited delirium, Elijah McClain, and emergency physicians

knowledge

explore

knowledge

Medical records are filled with copy

White House calls on federal agencies to crack down on AI abuses

Jerome Adams on the need for new antivirals for Covid

Sanofi CEO defends move to abandon profit guidance, boost research

Medicare proposal to cover medical devices draws a mixed reaction

Resistance to opioid

In Memoriam: Notable people who died in 2023

Tome Biosciences co

Hepatitis C has a cure — but many Americans still lack access to it

Ambulance rides for just $100? Advisers want major billing fixes

entertainment

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Artificial intelligence use in health care faces greater scrutiny in 2024

UCSF medical school apologizes for unethical prisoner experiments

Just how powerful is the placebo effect?

ACIP vaccine advisory panel sees its vacancies filled

Congress must protect the remaining independent doctors

entertainment

entertainment

hotspot

hotspot